{"abuse":["9.2 Abuse Diazepam is a benzodiazepine and a CNS depressant with a potential for abuse and addiction. Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. Even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. Abuse and misuse of benzodiazepines may lead to addiction. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. Benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders [see Warnings and Precautions ( 5.2 )] . The following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo. The following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. Death is more often associated with polysubstance use (especially benzodiazepines with other CNS depressants such as opioids and alcohol)."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the labeling: • Risks from Concomitant Use with Opioids [see Warnings and Precautions ( 5.1 )] • Abuse, Misuse, and Addiction [see Warnings and Precautions ( 5.2 )] • Dependence and Withdrawal Reactions [see Warnings and Precautions ( 5.3 )] • Central Nervous System Depression [see Warnings and Precautions ( 5.4 )] • Suicidal Behavior and Ideation [see Warnings and Precautions ( 5.5 )] • Worsening of Preexisting Depression [see Warnings and Precautions ( 5.6 )] • Paradoxical Reactions [see Warnings and Precautions ( 5.7 )] • Respiratory Depression and Apnea [see Warnings and Precautions ( 5.8 )] • Glaucoma [see Warnings and Precautions ( 5.9 )] • Neonatal Sedation and Withdrawal Syndrome [see Warnings and Precautions ( 5.10 )] The following adverse reactions associated with the use of diazepam were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions most commonly reported were drowsiness, fatigue, muscle weakness, and ataxia. The following adverse reactions have also been reported: Blood and lymphatic disorders: neutropenia Eye disorders: blurred vision, diplopia Gastrointestinal disorders: changes in salivation, including dry mouth and hypersalivation, gastrointestinal disturbances, constipation, nausea Hepatobiliary disorders: jaundice Injury, poisoning and procedural complications: falls and fractures. The risk is increased in those taking concomitant CNS depressants (including alcohol) and in geriatric patients. Investigations: elevated transaminases and alkaline phosphatase Nervous system disorders: vertigo, dizziness, dysarthria, tremor, headache Changes in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after diazepam therapy. Psychiatric disorders: disorientation, confusional state, decreased alertness, inappropriate behavior, emotional and mood disturbances, depression, acute hyperexcited states, hyperactivity, restlessness, stimulation, anxiety, nervousness, aggressiveness, agitation, anger, hostility, irritability, psychoses, delusions, hallucinations, insomnia, sleep disturbances, abnormal dreams, nightmares Anterograde amnesia has been reported, with the risk increasing at higher dosages. Amnestic effects may be associated with inappropriate behavior. Skin and subcutaneous tissue disorders: skin reactions Urogenital disorders: incontinence, changes in libido, urinary retention Vascular disorders: hypotension Most common adverse reactions are drowsiness, fatigue, muscle weakness, and ataxia ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"boxed_warning":["WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 )] . • The use of benzodiazepines, including diazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing diazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction [see Warnings and Precautions ( 5.2 )] . • The continued use of benzodiazepines, including diazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of diazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.3 )] . WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS See full prescribing information for complete boxed warning. • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. ( 5.1 , 7.1 ) • The use of benzodiazepines, including diazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing diazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction. ( 5.2 ) • Abrupt discontinuation or rapid dosage reduction of diazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage. ( 2.3 , 5.3 )"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis An increased incidence of liver tumors was observed in male mice and rats that were administered diazepam in the diet for 80 and 104 weeks, respectively at a dose of 75 mg/kg/day, approximately 9 and 18 times the maximum recommended human dose (MRHD) based on mg/m 2 body surface area, respectively. Mutagenesis The data currently available are inadequate to determine the mutagenic potential of diazepam. Impairment of Fertility Reproduction studies in rats showed decreases in the number of pregnancies and in the number of surviving offspring following administration of an oral dose of 100 mg/kg/day (approximately 24 times the MRHD based on mg/m 2 body surface area) prior to and during mating and throughout gestation and lactation. No adverse effects on fertility or offspring viability were noted up to a dose of 80 mg/kg/day (approximately 19 times the MRHD based on mg/m 2 body surface area)."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of diazepam for the listed indications [see Indications and Usage ( 1 )] is thought to involve potentiation of gamma aminobutyric acid (GABA), an inhibitory neurotransmitter, resulting from binding at the benzodiazepine site of the GABA A receptor. 12.2 Pharmacodynamics The effects of diazepam on the CNS are dependent on the dose administered, the route of administration, and the presence or absence of other medications. Diazepam-induced psychomotor impairment in women on contraceptives may be higher during the 7-day menstrual pause when off the hormone preparation than when taking the contraceptive. There is some limited evidence that benzodiazepines can increase the incidence of break-through bleeding in women with hormonal contraceptives. 12.3 Pharmacokinetics Absorption After oral administration >90% of diazepam is absorbed and the average time to achieve peak plasma concentrations is 1 to 1.5 hours with a range of 0.25 to 2.5 hours. Following daily dosing, diazepam levels reach a steady state within approximately 5 days and desmethyl diazepam levels reach a steady state within approximately 10 days. Average steady-state levels of diazepam after once daily administration are approximately twice as high as the peak levels of the drug after the first dose. Effect of Food Absorption is delayed and decreased when administered with a moderate fat meal. In the presence of food, mean lag times are approximately 45 minutes as compared with 15 minutes when fasting. There is also an increase in the average time to achieve peak concentrations to about 2.5 hours in the presence of food as compared with 1.25 hours when fasting. This results in an average decrease in C max of 20% in addition to a 27% decrease in AUC (range 15% to 50%) when administered with food. Distribution Diazepam and its metabolites are highly bound to plasma proteins (diazepam 98%). The volume of distribution at steady-state is 0.8 to 1.0 L/kg. Diazepam and its metabolites cross the blood-brain and placental barriers. The decline in the plasma concentration-time profile after oral administration is biphasic. The initial distribution phase has a half-life of approximately 1 hour, although it may range up to >3 hours. Both protein binding and volume of distribution of desmethyl-diazepam are similar to those of diazepam. Elimination Metabolism Oxidation of diazepam is mediated by cytochrome P450 isozymes; formation of desmethyl-diazepam mainly by CYP2C19 and CYP3A and 3-hydroxy-diazepam (temazepam) and oxazepam by CYP3A. Diazepam is mainly metabolized to pharmacologically active metabolites such as desmethyl-diazepam, a pathway accounting for 50 to 60% of total diazepam clearance; 3-hydroxylation (27% of total diazepam clearance) is slow, leading to only low plasma levels of the oxidation products temazepam and oxazepam. Temazepam and oxazepam are further conjugated to glucuronides. After multiple doses of diazepam, plasma concentration ratios of desmethyl-diazepam to diazepam were 1.1 ± 0.2, temazepam to diazepam 0.11 ± 0.05, and oxazepam to diazepam 0.09 ± 0.03. Diazepam has an initial rapid and extensive distribution phase being followed by a prolonged terminal elimination phase (half-life up to 48 hours). The terminal elimination half-life of the active metabolite N-desmethyldiazepam is up to 100 hours. Excretion Diazepam and its metabolites are excreted mainly in the urine, predominantly as their glucuronide conjugates. The clearance of diazepam is 20 to 30 mL/min in young adults. Diazepam accumulates upon multiple dosing and there is some evidence that the terminal elimination half-life is slightly prolonged. Specific Populations Geriatric Patients Age decreases the capacity of the liver for N-demethylation and 3-hydroxylation of diazepam. Elimination half-life increases by approximately 1 hour for each year of age beginning with a half-life of 20 hours at 20 years of age. This appears to be due to an increase in volume of distribution with age and a decrease in clearance. Consequently, geriatric patients may have lower peak concentrations, and on multiple dosing higher trough concentrations. It will also take longer to reach steady-state [see Dosage and Administration ( 2.2 ), Use in Specific Populations ( 8.5 )] . Conflicting information has been published on changes of plasma protein binding in geriatric patients. Pediatric Patients In pediatric patients 3 to 8 years of age the mean half-life of diazepam has been reported to be 18 hours [see Dosage and Administration ( 2.2 )] . Patients with Renal Impairment In chronic renal failure, elimination of diazepam, as indicated by clearance of unbound drug, was similar to that in healthy volunteers; thus steady-state concentrations of unbound diazepam at any given daily dose on the average should not be different between patients with renal impairment and healthy individuals. Patients with Hepatic Impairment In mild and moderate cirrhosis, average half-life is increased. The average increase has been variously reported from 2-fold to 5-fold, with individual half-lives over 500 hours reported. There is also an increase in volume of distribution, and average clearance decreases by almost half. Mean half-life is also prolonged with hepatic fibrosis to 90 hours (range 66 to 104 hours), with chronic active hepatitis to 60 hours (range 26 to 76 hours), and with acute viral hepatitis to 74 hours (range 49 to 129). In chronic active hepatitis, clearance is decreased by almost half [see Dosage and Administration ( 2.2 ), Use in Specific Populations ( 8.6 )] . Drug Interaction Studies The metabolism of diazepam and its main metabolite, desmethyl-diazepam depends on the cytochrome P450 isozymes CYP3A4 and CYP2C19. Modulators of these enzymes may lead to changes in diazepam disposition and effects. Inhibitors of CYP3A4 and CYP2C19 decrease metabolic rate and may lead to higher concentrations of diazepam and the desmethyl metabolite. Inducers of CYP3A4 and CYP2C19 may lead to lower concentrations of diazepam and the desmethly metabolite [see Drug Interactions ( 7.3 )] . Effect of Other Drugs on the Pharmacokinetics of Diazepam Enzyme Inhibitors Grapefruit juice contains strong inhibitors of CYP3A4. Diazepam exposure was increased and time to reach maximum concentration was delayed when diazepam was given with grapefruit juice instead of water [see Drug Interactions ( 7.3 )] . Antimycotic azole derivatives inhibit CYP3A4 and CYP2C19 pathways and lead to increased exposure to diazepam and prolonged elimination half-life of diazepam [see Drug Interactions ( 7.3 )] . The serotonin reuptake inhibitor fluvoxamine is also an inhibitor of both of diazepam’s degradation pathways and increased not only exposure to diazepam and prolonged its elimination half-life but also increased exposure and time to reach steady-state of the desmethyl metabolite. Fluoxetine showed a more moderate effect on diazepam AUC [see Drug Interactions ( 7.3 )] . Combined hormonal contraceptives appear to reduce the clearance and prolong elimination half-life of diazepam. Proton pump inhibitors such as omeprazole, esomeprazole, lansoprazole, pantoprazole may increase the diazepam AUC. The histamine H 2 -receptor antagonist cimetidine, an inhibitor of multiple CYP isozymes, including CYP3A4 and CYP2C19, reduces the clearance of diazepam and of desmethyl-diazepam and results in higher exposure and a prolonged elimination half-life of diazepam and its main metabolite [see Drug Interactions ( 7.3 )] . No such pharmacokinetic interaction was seen with the H 2 -receptor antagonists ranitidine and famotidine. Disulfiram inhibits the metabolism of diazepam and likely the further metabolism of diazepam’s active metabolites. Antituberculosis therapy may change the disposition of diazepam. In the presence of isoniazid, diazepam mean exposure (AUC) and half-life were increased. The calcium channel blocker diltiazem, a substrate for the same CYP isozymes as diazepam and an inhibitor of CYP3A4, increased AUC and prolonged half-life of diazepam [see Drug Interactions ( 7.3 )] . The primary metabolite of idelalisib is a strong CYP3A4 inhibitor and increases the serum concentrations of diazepam [see Drug Interactions ( 7.3 )] . The psychostimulants modafinil and armodafinil induce CYP3A4 and inhibit CYP2C19; they may prolong the elimination of diazepam [see Drug Interactions ( 7.3 )] . Enzyme Inducers Rifampicin and carbamazepine, potent inducers of CYP3A4, may lead to a reduction in exposure of diazepam [see Drug Interactions ( 7.3 )] . Antacids Antacids may lower the diazepam peak but have no effect on the extent of absorption of diazepam. Diazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The time to reach peak concentrations are 20 to 25 min longer for diazepam in presence of antacids. Effect of Diazepam on the Pharmacokinetics of Other Drugs Diazepam has not been found to induce or inhibit metabolizing enzymes. Diazepam is a substrate for CYP2C19 and CYP3A4; therefore, diazepam may interfere with the metabolism and increase the exposure of drugs which are sensitive substrates for CYP2C19 and CYP3A4.13"],"contraindications":["4 CONTRAINDICATIONS Diazepam is contraindicated in patients with: • Known hypersensitivity to diazepam or any of the excipients of diazepam • Acute narrow-angle glaucoma [see Warnings and Precautions ( 5.9 )] • Known hypersensitivity to diazepam or any excipients of diazepam ( 4 ) • Acute narrow-angle glaucoma ( 4 )"],"controlled_substance":["9.1 Controlled Substance Diazepam oral solution contains diazepam, a Schedule IV controlled substance."],"dependence":["9.3 Dependence Physical Dependence Diazepam may produce physical dependence from continued therapy. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses) and those who have had longer durations of use [see Warnings and Precautions ( 5.3 )] . To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.3 )] . Acute Withdrawal Signs and Symptoms Acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. More severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures, and suicidality. Protracted Withdrawal Syndrome Protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. Protracted withdrawal symptoms may last weeks to more than 12 months. As a result, there may be difficulty in differentiating withdrawal symptoms from potential re-emergence or continuation of symptoms for which the benzodiazepine was being used. Tolerance Tolerance to diazepam may develop from continued therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). Tolerance to the therapeutic effect of diazepam may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines."],"description":["11 DESCRIPTION Diazepam is a benzodiazepine derivative. Chemically, diazepam is 7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2 H -1,4-benzodiazepin-2-one. It is an off-white to yellow, crystalline powder, insoluble in water and has a molecular weight of 284.75. Its structural formula is as follows: The flavored 5 mg/5 mL Oral Solution contains bitterness modifier, citric acid, D&C Yellow No. 10, FD&C Red No. 40, polyethylene glycol, propylene glycol, sodium citrate, sorbitol, water and wintergreen coriander spice blend. diazepam structural formula image"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • Recommended oral dosage in adults less than 65 years of age: ( 2.1 ) Indication Recommended Oral Dosage Treatment of anxiety disorders 2 mg to 10 mg, two to four times daily Short-term treatment of anxiety symptoms 2 mg to 10 mg, two to four times daily Treatment of acute alcohol withdrawal * 10 mg, three to four times during the first 24 hours; after 24 hours reduce to 5 mg, three to four times daily, as needed Recommended dosage is intended for most patients. Based on severity of symptoms some patients may require higher dosages. In such cases, increase dosage gradually. Adjunctive treatment of skeletal muscle spasm * 2 mg to 10 mg, three to four times daily Adjunctive treatment of seizure disorders 2 mg to 10 mg, two to four times daily * See full prescribing information for complete indication ( 1 ) • See full prescribing information for recommended oral dosage in pediatric patients 6 months of age and older, geriatric or debilitated patients, and patients with hepatic impairment ( 2.2 ) 2.1 Recommended Dosage in Adults Less Than 65 Years of Age Table 1 provides the recommended oral dosage of diazepam by indication for adults less than 65 years of age. Table 1: Recommended Dosage in Adults Less than 65 Years of Age Indication Recommended Oral Dosage Treatment of anxiety disorders 2 mg to 10 mg, two to four times daily Short-term treatment of anxiety symptoms 2 mg to 10 mg, two to four times daily Treatment of acute alcohol withdrawal * 10 mg, three to four times during the first 24 hours; after 24 hours reduce dosage to 5 mg, three to four times daily, as needed. The recommended dosage is intended for most patients. However, based on severity of symptoms, some patients may require higher dosages. In such cases, increase the dosage gradually, as needed and tolerated, to reduce the risk of adverse reactions. Adjunctive treatment of skeletal muscle spasm * 2 mg to 10 mg, three to four times daily Adjunctive treatment of seizure disorders 2 mg to 10 mg, two to four times daily * [see Indications and Usage ( 1 ) for the complete indication] 2.2 Recommended Dosage in Specific Populations Pediatric Patients 6 Months of Age and Older The recommended starting dosage in pediatric patients 6 months of age and older is 1 mg to 2.5 mg orally, three or four times daily. Increase the dosage gradually as needed and tolerated [see Use in Specific Populations ( 8.4 )] . Geriatric or Debilitated Patients The recommended starting dosage in geriatric patients 65 years of age and older or debilitated patients is 2 mg to 2.5 mg orally, once or twice daily. Increase the dosage gradually as needed and tolerated [see Use in Specific Populations ( 8.5 , 8.8 )] . Patients with Hepatic Impairment In patients with mild or moderate hepatic impairment, reduce the recommended dosage by half compared to those with normal hepatic function [see Dosage and Administration ( 2.1 )] . Diazepam is not recommended in patients with severe hepatic impairment [see Use in Specific Populations ( 8.6 )] . 2.3 Discontinuation or Dosage Reduction of Diazepam To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly [see Warnings and Precautions ( 5.3 ), Drug Abuse and Dependence ( 9.3 )] ."],"dosage_and_administration_table":["<table styleCode=\"Noautorules\" width=\"100%\"> <col width=\"35%\"/> <col width=\"65%\"/> <tbody> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Indication</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Recommended Oral Dosage</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Treatment of anxiety disorders</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2 mg to 10 mg, two to four times daily</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Short-term treatment of anxiety symptoms</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2 mg to 10 mg, two to four times daily</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Treatment of acute</paragraph> <paragraph>alcohol withdrawal<sup>*</sup> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>10 mg, three to four times during the first 24</paragraph> <paragraph>hours; after 24 hours reduce to 5 mg, three to four</paragraph> <paragraph>times daily, as needed</paragraph> <paragraph>Recommended dosage is intended for most</paragraph> <paragraph>patients. Based on severity of symptoms some</paragraph> <paragraph>patients may require higher dosages. In such cases,</paragraph> <paragraph>increase dosage gradually.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Adjunctive treatment of skeletal muscle spasm<sup>*</sup> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2 mg to 10 mg, three to four times daily</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Adjunctive treatment of seizure disorders</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>2 mg to 10 mg, two to four times daily</paragraph> </td> </tr> </tbody> </table>","<table styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 1: Recommended Dosage in Adults Less than 65 Years of Age</caption> <col width=\"28%\"/> <col width=\"72%\"/> <tbody> <tr> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Indication</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Recommended Oral Dosage</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Treatment of anxiety disorders</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2 mg to 10 mg, two to four times daily</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Short-term treatment of anxiety symptoms</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2 mg to 10 mg, two to four times daily</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Treatment of acute alcohol withdrawal<sup>*</sup> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>10 mg, three to four times during the first 24 hours; after 24 hours reduce dosage to</paragraph> <paragraph>5 mg, three to four times daily, as needed.</paragraph> <paragraph>The recommended dosage is intended for most patients. However, based on severity</paragraph> <paragraph>of symptoms, some patients may require higher dosages. In such cases, increase the</paragraph> <paragraph>dosage gradually, as needed and tolerated, to reduce the risk of adverse reactions.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Adjunctive treatment of skeletal muscle spasm<sup>*</sup> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2 mg to 10 mg, three to four times daily</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Adjunctive treatment of seizure disorders</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>2 mg to 10 mg, two to four times daily</paragraph> </td> </tr> </tbody> </table>"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Diazepam Oral Solution The 5 mg per 5 mL oral solution is supplied as a (wintergreen-spice flavored) clear, orange-colored solution. Each 5 mL of diazepam oral solution contains 5 mg of diazepam ( 3 )"],"drug_abuse_and_dependence":["9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance Diazepam oral solution contains diazepam, a Schedule IV controlled substance. 9.2 Abuse Diazepam is a benzodiazepine and a CNS depressant with a potential for abuse and addiction. Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. Even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. Abuse and misuse of benzodiazepines may lead to addiction. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. Benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders [see Warnings and Precautions ( 5.2 )] . The following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo. The following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. Death is more often associated with polysubstance use (especially benzodiazepines with other CNS depressants such as opioids and alcohol). 9.3 Dependence Physical Dependence Diazepam may produce physical dependence from continued therapy. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses) and those who have had longer durations of use [see Warnings and Precautions ( 5.3 )] . To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.3 )] . Acute Withdrawal Signs and Symptoms Acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. More severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures, and suicidality. Protracted Withdrawal Syndrome Protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. Protracted withdrawal symptoms may last weeks to more than 12 months. As a result, there may be difficulty in differentiating withdrawal symptoms from potential re-emergence or continuation of symptoms for which the benzodiazepine was being used. Tolerance Tolerance to diazepam may develop from continued therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). Tolerance to the therapeutic effect of diazepam may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines."],"drug_interactions":["7 DRUG INTERACTIONS • CYP3A4 and CYP2C19 Inhibitors: Based on tolerability, consider reducing dosage of diazepam. Avoid food or drink containing grapefruit ( 7.3 ) • CYP3A4 and CYP2C19 Inducers: Based on clinical response, consider increasing dosage of diazepam ( 7.3 ) 7.1 Effect of Concomitant Use of Benzodiazepines and Opioids Limit dosage and duration of concomitant use of diazepam and opioids and monitor patients closely for respiratory depression and sedation. The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at gamma-aminobutyric acid (GABA A ) sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists [see Warnings and Precautions ( 5.1 )] . 7.2 CNS Depressants and Alcohol Avoid consumption of alcohol and use caution during concomitant use of other medications that produce CNS depression with diazepam. Diazepam produces additive CNS depressant effects, which can include potentially fatal respiratory depression, when used concomitantly with other medications that produce CNS depression, or with consumption of alcohol [see Warnings and Precautions ( 5.4 , 5.8 )] . 7.3 Effects of Other Drugs on Diazepam Table 3 describes drug interactions where concomitant use of another drug affects diazepam. Table 3: Concomitant Use of Other Drugs That Affect Diazepam CYP3A4 or CYP2C19 Inhibitors See www.fda.gov/CYPandTransporterInteractingDrugs for examples of CYP3A4 and CYP2C19 inhibitors and inducers. Prevention or Management Based on tolerability, consider reducing the dosage of diazepam during concomitant use with CYP3A4 or CYP2C19 inhibitors. Avoid food or drink containing grapefruit juice during treatment with diazepam. Mechanism and Clinical Effect(s) Concomitant use of CYP3A4 or CYP2C19 inhibitors with diazepam increases the exposure of diazepam and may lead to increased and prolonged sedation. CYP3A4 or CYP2C19 Inducers Prevention or Management Based on clinical response, consider increasing the dosage of diazepam during concomitant use with CYP3A4 or CYP2C19 inducers. Mechanism and Clinical Effect(s) Concomitant use of diazepam with CYP3A4 or CYP2C19 inducers may decrease the exposure of diazepam and lead to decreased efficacy."],"drug_interactions_table":["<table styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 3: Concomitant Use of Other Drugs That Affect Diazepam</caption> <col width=\"32%\"/> <col width=\"68%\"/> <tbody> <tr> <td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">CYP3A4 or CYP2C19 Inhibitors</content> <footnote ID=\"_Ref243341791\">See <linkHtml href=\"http://www.fda.gov/CYPandTransporterInteractingDrugs\">www.fda.gov/CYPandTransporterInteractingDrugs</linkHtml> for examples of CYP3A4 and CYP2C19 inhibitors and inducers.</footnote> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"italics\">Prevention or Management</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Based on tolerability, consider reducing the dosage of diazepam during concomitant use with CYP3A4 or CYP2C19 inhibitors. Avoid food or drink containing grapefruit juice during treatment with diazepam.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"italics\">Mechanism and Clinical Effect(s)</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Concomitant use of CYP3A4 or CYP2C19 inhibitors with diazepam increases the exposure of diazepam and may lead to increased and prolonged sedation.</paragraph> </td> </tr> <tr> <td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">CYP3A4 or CYP2C19 Inducers</content> <footnoteRef IDREF=\"_Ref243341791\"/> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"italics\">Prevention or Management</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Based on clinical response, consider increasing the dosage of diazepam during concomitant use with CYP3A4 or CYP2C19 inducers.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> <content styleCode=\"italics\">Mechanism and Clinical Effect(s)</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Concomitant use of diazepam with CYP3A4 or CYP2C19 inducers may decrease the exposure of diazepam and lead to decreased efficacy.</paragraph> </td> </tr> </tbody> </table>"],"effective_time":"20261001","geriatric_use":["8.5 Geriatric Use Extensive accumulation of diazepam and its major metabolite, des-methyldiazepam, has been noted following chronic administration of diazepam in healthy geriatric male subjects [see Clinical Pharmacology ( 12.3 )] . Metabolites of diazepam are substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function than in patients with normal renal function. Because geriatric patients are more likely to have decreased renal function, care should be taken in dosage selection. A lower starting dosage is recommended, and the dosage should be increased gradually as needed and tolerated, to reduce the risk of adverse reactions [see Dosage and Administration ( 2.2 )] . Paradoxical reactions are more likely to occur in geriatric patients compared to younger adult patients [see Warning and Precautions ( 5.7 )] ."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied Diazepam Oral Solution The 5 mg per 5 mL oral solution is supplied as a (wintergreen-spice flavored) clear, orange-colored solution. NDC 0054-3188-63: Bottle of 500 mL Storage and Handling Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP/NF."],"id":"6d097388-f2e0-4bd4-9faf-1b6b9b949d54","indications_and_usage":["1 INDICATIONS AND USAGE Diazepam is indicated for the: • Treatment of anxiety disorders • Short-term treatment of anxiety symptoms • Treatment of tremor, acute agitation, hallucinosis, and impending delirium tremens or delirium tremens in acute alcohol withdrawal • Adjunctive treatment of skeletal muscle spasm due to: o reflex spasm to local pathology o spasticity caused by upper motor neuron disorders o athetosis o stiff-person syndrome • Adjunctive treatment of seizure disorders Limitations of Use • The effectiveness of diazepam for long-term use (greater than 4 months) has not been evaluated. • Diazepam is not recommended as maintenance monotherapy for the treatment of seizure disorders. Diazepam is a benzodiazepine indicated for the: ( 1 ) • Treatment of anxiety disorders • Short-term treatment of anxiety symptoms • Treatment of tremor, acute agitation, hallucinosis, and impending delirium tremens or delirium tremens in acute alcohol withdrawal • Adjunctive treatment of skeletal muscle spasm due to reflex spasm to local pathology, spasticity caused by upper motor neuron disorders, athetosis, or stiff-person syndrome • Adjunctive treatment of seizure disorders Limitations of Use • The effectiveness of diazepam for long-term use (greater than 4 months) has not been evaluated ( 1 ) • Diazepam is not recommended as maintenance monotherapy for the treatment of seizure disorders ( 1 )"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Risks from Concomitant Use with Opioids Advise both patients and caregivers about the risks of potentially fatal respiratory depression and sedation when diazepam is used with opioids and not to use such drugs concomitantly unless supervised by a healthcare provider [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 )] . Abuse, Misuse, and Addiction Inform patients that the use of diazepam, even at recommended dosages, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose and death, especially when used in combination with other medications (e.g., opioid analgesics), alcohol, and/or illicit substances. Inform patients about the signs and symptoms of benzodiazepine abuse, misuse, and addiction; to seek medical help if they develop these signs and/or symptoms; and on the proper disposal of unused drug [see Warnings and Precautions ( 5.2 ), Drug Abuse and Dependence ( 9.2 )] . Withdrawal Reactions Inform patients that the continued use of diazepam may lead to clinically significant physical dependence and that abrupt discontinuation or rapid dosage reduction of diazepam may precipitate acute withdrawal reactions, which can be life-threatening. Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months. Instruct patients that discontinuation or dosage reduction of diazepam may require a slow taper [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.3 ), Drug Abuse and Dependence ( 9.3 )] . Central Nervous System Depression Inform patients that diazepam may produce CNS depression. Advise patients not to engage in hazardous occupations or activities requiring complete mental alertness such as driving a motor vehicle or operating heavy machinery. Also advise patients to avoid use of alcohol while taking diazepam [see Warnings and Precautions ( 5.4 ), Drug Interactions ( 7.2 )] . Suicidal Behavior and Ideation Counsel patients, their caregivers, and families that AEDs, including diazepam, may increase the risk of suicidal thoughts and behavior and advise them of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Advise patients to report behaviors of concern immediately to healthcare providers [see Warnings and Precautions ( 5.5 )] . Worsening of Preexisting Depression Inform patients that diazepam may worsen preexisting depression. Advise patients to report symptoms of worsening depression to their healthcare provider [see Warnings and Precautions ( 5.6 )] . Paradoxical Reactions Inform patients that paradoxical reactions such as such as aggression, agitation, anger, irritability, psychoses, hallucinations, anxiety, and nightmares have been reported during benzodiazepine use. Advise patients to contact their healthcare provider if paradoxical reactions occur [see Warnings and Precautions ( 5.7 )] . Concomitant Medications Advise patients to inform their healthcare provider of all medicines they take, including prescription and nonprescription medications, vitamins and herbal supplements [see Drug Interactions ( 7 )] . Grapefruit Juice Advise patients to avoid eating grapefruit or drinking grapefruit juice while taking diazepam [see Drug Interactions ( 7.3 )] . Pregnancy Advise pregnant women that the use of diazepam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying and feeding difficulties) in newborns [see Warnings and Precautions ( 5.10 ), Use in Specific Populations ( 8.1 )] . Instruct patients to inform their healthcare providers if they are pregnant or intend to become pregnant during treatment with diazepam. Advise patients that there are pregnancy exposure registries that monitor pregnancy outcomes in women exposed to diazepam during pregnancy [see Use in Specific Populations ( 8.1 )] . Lactation Counsel patients that diazepam, the active ingredient in diazepam, is excreted in breast milk. Instruct patients to inform their healthcare provider if they are breastfeeding or intend to breastfeed. Instruct breastfeeding patients who take diazepam to monitor their infants for excessive sedation, poor feeding and poor weight gain, and to seek medical attention if they notice these signs [see Use in Specific Populations ( 8.2 )] . Distributed by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 C50001281/02 Revised October 2026"],"mechanism_of_action":["12.1 Mechanism of Action The mechanism of action of diazepam for the listed indications [see Indications and Usage ( 1 )] is thought to involve potentiation of gamma aminobutyric acid (GABA), an inhibitory neurotransmitter, resulting from binding at the benzodiazepine site of the GABA A receptor."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis An increased incidence of liver tumors was observed in male mice and rats that were administered diazepam in the diet for 80 and 104 weeks, respectively at a dose of 75 mg/kg/day, approximately 9 and 18 times the maximum recommended human dose (MRHD) based on mg/m 2 body surface area, respectively. Mutagenesis The data currently available are inadequate to determine the mutagenic potential of diazepam. Impairment of Fertility Reproduction studies in rats showed decreases in the number of pregnancies and in the number of surviving offspring following administration of an oral dose of 100 mg/kg/day (approximately 24 times the MRHD based on mg/m 2 body surface area) prior to and during mating and throughout gestation and lactation. No adverse effects on fertility or offspring viability were noted up to a dose of 80 mg/kg/day (approximately 19 times the MRHD based on mg/m 2 body surface area)."],"openfda":{"application_number":["ANDA070928"],"brand_name":["Diazepam"],"generic_name":["DIAZEPAM"],"is_original_packager":[true],"manufacturer_name":["Hikma Pharmaceuticals USA Inc."],"nui":["N0000175694","M0002356"],"package_ndc":["0054-3188-63"],"pharm_class_cs":["Benzodiazepines [CS]"],"pharm_class_epc":["Benzodiazepine [EPC]"],"product_ndc":["0054-3188"],"product_type":["HUMAN PRESCRIPTION DRUG"],"route":["ORAL"],"rxcui":["309843"],"spl_id":["6d097388-f2e0-4bd4-9faf-1b6b9b949d54"],"spl_set_id":["9e85abed-1a8b-4762-a31f-f2c7f196b8af"],"substance_name":["DIAZEPAM"],"unii":["Q3JTX2Q7TU"],"upc":["0300543188631"]},"overdosage":["10 OVERDOSAGE Overdosage of benzodiazepines is characterized by central nervous system depression ranging from drowsiness to coma. In mild to moderate cases, symptoms can include drowsiness, confusion, dysarthria, lethargy, hypnotic state, diminished reflexes, ataxia, and hypotonia. Rarely, paradoxical or disinhibitory reactions (including agitation, irritability, impulsivity, violent behavior, confusion, restlessness, excitement, and talkativeness) may occur. In severe overdosage cases, patients may develop respiratory depression and coma. Overdosage of benzodiazepines in combination with other CNS depressants (including alcohol and opioids) may be fatal [see Warnings and Precautions ( 5.2 )] . Markedly abnormal (lowered or elevated) blood pressure, heart rate, or respiratory rate raise the concern that additional drugs and/or alcohol are involved in the overdosage. In managing benzodiazepine overdosage, employ general supportive measures, including intravenous fluids and airway maintenance. Flumazenil, a specific benzodiazepine receptor antagonist indicated for the complete or partial reversal of the sedative effects of benzodiazepines in the management of benzodiazepine overdosage, can lead to withdrawal and adverse reactions, including seizures, particularly in the context of mixed overdosage with drugs that increase seizure risk (e.g., tricyclic and tetracyclic antidepressants) and in patients with long-term benzodiazepine use and physical dependency. The risk of withdrawal seizures with flumazenil use may be increased in patients with epilepsy. Flumazenil is contraindicated in patients who have received a benzodiazepine for control of a potentially life-threatening condition (e.g., status epilepticus). If the decision is made to use flumazenil, it should be used as an adjunct to, not as a substitute for, supportive management of benzodiazepine overdosage. See the flumazenil injection Prescribing Information. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations."],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 0054- 3188 -63 500 mL Diazepam Oral Solution CIV 5 mg per 5 mL Rx only diazepam oral solution 5mg per 5mL 500mL bottle label image"],"pediatric_use":["8.4 Pediatric Use Diazepam oral solution is indicated for use in pediatric patients for the: • Treatment of anxiety disorders • Short-term treatment of anxiety symptoms • Treatment of tremor, acute agitation, hallucinosis, and impending delirium tremens or delirium tremens in acute alcohol withdrawal • Adjunctive treatment of skeletal muscle spasm due to: o reflex spasm to local pathology o spasticity caused by upper motor neuron disorders o athetosis o stiff-person syndrome • Adjunctive treatment of seizure disorders Paradoxical reactions are more likely to occur in pediatric patients than in adult patients [see Warnings and Precautions ( 5.7 )] . Diazepam is not recommended for use in pediatric patients less than 6 months of age. Prolonged central nervous system depression has been observed in neonates treated with diazepam."],"pharmacodynamics":["12.2 Pharmacodynamics The effects of diazepam on the CNS are dependent on the dose administered, the route of administration, and the presence or absence of other medications. Diazepam-induced psychomotor impairment in women on contraceptives may be higher during the 7-day menstrual pause when off the hormone preparation than when taking the contraceptive. There is some limited evidence that benzodiazepines can increase the incidence of break-through bleeding in women with hormonal contraceptives."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption After oral administration >90% of diazepam is absorbed and the average time to achieve peak plasma concentrations is 1 to 1.5 hours with a range of 0.25 to 2.5 hours. Following daily dosing, diazepam levels reach a steady state within approximately 5 days and desmethyl diazepam levels reach a steady state within approximately 10 days. Average steady-state levels of diazepam after once daily administration are approximately twice as high as the peak levels of the drug after the first dose. Effect of Food Absorption is delayed and decreased when administered with a moderate fat meal. In the presence of food, mean lag times are approximately 45 minutes as compared with 15 minutes when fasting. There is also an increase in the average time to achieve peak concentrations to about 2.5 hours in the presence of food as compared with 1.25 hours when fasting. This results in an average decrease in C max of 20% in addition to a 27% decrease in AUC (range 15% to 50%) when administered with food. Distribution Diazepam and its metabolites are highly bound to plasma proteins (diazepam 98%). The volume of distribution at steady-state is 0.8 to 1.0 L/kg. Diazepam and its metabolites cross the blood-brain and placental barriers. The decline in the plasma concentration-time profile after oral administration is biphasic. The initial distribution phase has a half-life of approximately 1 hour, although it may range up to >3 hours. Both protein binding and volume of distribution of desmethyl-diazepam are similar to those of diazepam. Elimination Metabolism Oxidation of diazepam is mediated by cytochrome P450 isozymes; formation of desmethyl-diazepam mainly by CYP2C19 and CYP3A and 3-hydroxy-diazepam (temazepam) and oxazepam by CYP3A. Diazepam is mainly metabolized to pharmacologically active metabolites such as desmethyl-diazepam, a pathway accounting for 50 to 60% of total diazepam clearance; 3-hydroxylation (27% of total diazepam clearance) is slow, leading to only low plasma levels of the oxidation products temazepam and oxazepam. Temazepam and oxazepam are further conjugated to glucuronides. After multiple doses of diazepam, plasma concentration ratios of desmethyl-diazepam to diazepam were 1.1 ± 0.2, temazepam to diazepam 0.11 ± 0.05, and oxazepam to diazepam 0.09 ± 0.03. Diazepam has an initial rapid and extensive distribution phase being followed by a prolonged terminal elimination phase (half-life up to 48 hours). The terminal elimination half-life of the active metabolite N-desmethyldiazepam is up to 100 hours. Excretion Diazepam and its metabolites are excreted mainly in the urine, predominantly as their glucuronide conjugates. The clearance of diazepam is 20 to 30 mL/min in young adults. Diazepam accumulates upon multiple dosing and there is some evidence that the terminal elimination half-life is slightly prolonged. Specific Populations Geriatric Patients Age decreases the capacity of the liver for N-demethylation and 3-hydroxylation of diazepam. Elimination half-life increases by approximately 1 hour for each year of age beginning with a half-life of 20 hours at 20 years of age. This appears to be due to an increase in volume of distribution with age and a decrease in clearance. Consequently, geriatric patients may have lower peak concentrations, and on multiple dosing higher trough concentrations. It will also take longer to reach steady-state [see Dosage and Administration ( 2.2 ), Use in Specific Populations ( 8.5 )] . Conflicting information has been published on changes of plasma protein binding in geriatric patients. Pediatric Patients In pediatric patients 3 to 8 years of age the mean half-life of diazepam has been reported to be 18 hours [see Dosage and Administration ( 2.2 )] . Patients with Renal Impairment In chronic renal failure, elimination of diazepam, as indicated by clearance of unbound drug, was similar to that in healthy volunteers; thus steady-state concentrations of unbound diazepam at any given daily dose on the average should not be different between patients with renal impairment and healthy individuals. Patients with Hepatic Impairment In mild and moderate cirrhosis, average half-life is increased. The average increase has been variously reported from 2-fold to 5-fold, with individual half-lives over 500 hours reported. There is also an increase in volume of distribution, and average clearance decreases by almost half. Mean half-life is also prolonged with hepatic fibrosis to 90 hours (range 66 to 104 hours), with chronic active hepatitis to 60 hours (range 26 to 76 hours), and with acute viral hepatitis to 74 hours (range 49 to 129). In chronic active hepatitis, clearance is decreased by almost half [see Dosage and Administration ( 2.2 ), Use in Specific Populations ( 8.6 )] . Drug Interaction Studies The metabolism of diazepam and its main metabolite, desmethyl-diazepam depends on the cytochrome P450 isozymes CYP3A4 and CYP2C19. Modulators of these enzymes may lead to changes in diazepam disposition and effects. Inhibitors of CYP3A4 and CYP2C19 decrease metabolic rate and may lead to higher concentrations of diazepam and the desmethyl metabolite. Inducers of CYP3A4 and CYP2C19 may lead to lower concentrations of diazepam and the desmethly metabolite [see Drug Interactions ( 7.3 )] . Effect of Other Drugs on the Pharmacokinetics of Diazepam Enzyme Inhibitors Grapefruit juice contains strong inhibitors of CYP3A4. Diazepam exposure was increased and time to reach maximum concentration was delayed when diazepam was given with grapefruit juice instead of water [see Drug Interactions ( 7.3 )] . Antimycotic azole derivatives inhibit CYP3A4 and CYP2C19 pathways and lead to increased exposure to diazepam and prolonged elimination half-life of diazepam [see Drug Interactions ( 7.3 )] . The serotonin reuptake inhibitor fluvoxamine is also an inhibitor of both of diazepam’s degradation pathways and increased not only exposure to diazepam and prolonged its elimination half-life but also increased exposure and time to reach steady-state of the desmethyl metabolite. Fluoxetine showed a more moderate effect on diazepam AUC [see Drug Interactions ( 7.3 )] . Combined hormonal contraceptives appear to reduce the clearance and prolong elimination half-life of diazepam. Proton pump inhibitors such as omeprazole, esomeprazole, lansoprazole, pantoprazole may increase the diazepam AUC. The histamine H 2 -receptor antagonist cimetidine, an inhibitor of multiple CYP isozymes, including CYP3A4 and CYP2C19, reduces the clearance of diazepam and of desmethyl-diazepam and results in higher exposure and a prolonged elimination half-life of diazepam and its main metabolite [see Drug Interactions ( 7.3 )] . No such pharmacokinetic interaction was seen with the H 2 -receptor antagonists ranitidine and famotidine. Disulfiram inhibits the metabolism of diazepam and likely the further metabolism of diazepam’s active metabolites. Antituberculosis therapy may change the disposition of diazepam. In the presence of isoniazid, diazepam mean exposure (AUC) and half-life were increased. The calcium channel blocker diltiazem, a substrate for the same CYP isozymes as diazepam and an inhibitor of CYP3A4, increased AUC and prolonged half-life of diazepam [see Drug Interactions ( 7.3 )] . The primary metabolite of idelalisib is a strong CYP3A4 inhibitor and increases the serum concentrations of diazepam [see Drug Interactions ( 7.3 )] . The psychostimulants modafinil and armodafinil induce CYP3A4 and inhibit CYP2C19; they may prolong the elimination of diazepam [see Drug Interactions ( 7.3 )] . Enzyme Inducers Rifampicin and carbamazepine, potent inducers of CYP3A4, may lead to a reduction in exposure of diazepam [see Drug Interactions ( 7.3 )] . Antacids Antacids may lower the diazepam peak but have no effect on the extent of absorption of diazepam. Diazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The time to reach peak concentrations are 20 to 25 min longer for diazepam in presence of antacids. Effect of Diazepam on the Pharmacokinetics of Other Drugs Diazepam has not been found to induce or inhibit metabolizing enzymes. Diazepam is a substrate for CYP2C19 and CYP3A4; therefore, diazepam may interfere with the metabolism and increase the exposure of drugs which are sensitive substrates for CYP2C19 and CYP3A4.13"],"pregnancy":["8.1 Pregnancy Pregnancy Exposure Registries There are pregnancy exposure registries that monitor pregnancy outcomes in women exposed to psychiatric medications and antiepileptic drugs (AEDs), including diazepam, during pregnancy. Healthcare providers are encouraged to advise patients to register by contacting the appropriate registry below: • The National Pregnancy Registry for Psychiatric Medications by calling 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/othermedications/. • The North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334 or online at http://www.aedpregnancyregistry.org/. Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see Warnings and Precautions ( 5.10 ) and Clinical Considerations] . Available data from published observational studies of pregnant women exposed to benzodiazepines do not support a clear association with benzodiazepines and major birth defects (see Data) . There are risks to the mother and fetus associated with untreated epilepsy during pregnancy (see Clinical Considerations) . In animal studies, administration of diazepam during the organogenesis period of pregnancy resulted in increased incidences of fetal malformations at doses greater than those used clinically. Data for diazepam and other benzodiazepines suggest the possibility of increased neuronal cell death and long-term effects on neurobehavioral and immunological function based on findings in animals following prenatal or early postnatal exposure at clinically relevant doses (see Data) . The background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryofetal Risk Epilepsy, with or without exposure to antiepileptic drugs, has been associated with several adverse outcomes during pregnancy, including preeclampsia, preterm labor, antepartum and postpartum hemorrhage, placental abruption, poor fetal growth, prematurity, fetal death, and maternal mortality. The risk of maternal or fetal injury may be greatest for patients with untreated or poorly controlled convulsive seizures. Females with epilepsy should not discontinue diazepam abruptly due to the risk of status epilepticus or severe seizures, which may be life-threatening [see Warnings and Precautions ( 5.3 )] . Fetal/Neonatal Adverse Reactions Benzodiazepines cross the placenta and may produce respiratory depression, hypotonia, and sedation in neonates. Monitor neonates exposed to diazepam during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor neonates exposed to diazepam during pregnancy for signs of withdrawal. Manage these neonates accordingly [see Warnings and Precautions ( 5.10 )] . Data Human Data Published data from observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects. Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, recent case-control and cohort studies of benzodiazepine use during pregnancy were adjusted for confounding exposures to alcohol, tobacco and other medications; these studies did not support an association with benzodiazepines and major birth defects. Animal Data Diazepam has been shown to cause malformations when administered orally to pregnant mice and hamsters during the period of organogenesis at doses of 100 mg/kg/day or greater, approximately 12 and 20 times the maximum recommended human dose (MRHD) based on mg/m 2 body surface area, respectively. Cleft palate and encephalopathy were the most common and consistently reported malformations produced at maternally toxic doses of diazepam. Rodent studies have indicated that prenatal exposure to diazepam doses similar to those used clinically can produce long-term changes in cellular immune responses, brain neurochemistry, and behavior. In published animal studies, administration of benzodiazepines or other drugs that enhance GABAergic inhibition to neonatal rats has been reported to result in widespread apoptotic neurodegeneration in the developing brain at clinically relevant plasma concentrations. The window of vulnerability to these changes in rats (postnatal days 0 to 14) includes a period of brain development that takes place during the third trimester of pregnancy in humans."],"set_id":"9e85abed-1a8b-4762-a31f-f2c7f196b8af","spl_medguide":["MEDICATION GUIDE Diazepam Oral Solution, C-IV, 5 mg per 5 mL (dye azʹ e pam) What is the most important information I should know about Diazepam Oral Solution? Diazepam Oral Solution may cause serious side effects, including: • Diazepam Oral Solution is a benzodiazepine medicine. Taking benzodiazepines with opioid medicines, alcohol, or other central nervous system (CNS) depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death. Get emergency help right away if any of the following happens: o shallow or slowed breathing, o breathing stops (which may lead to the heart stopping), o excessive sleepiness (sedation). • Risk of abuse, misuse, and addiction. There is a risk of abuse, misuse, and addiction with benzodiazepines, including Diazepam Oral Solution, which can lead to overdose and serious side effects including coma and death. o Serious side effects including coma and death have happened in people who have abused or misused benzodiazepines, including Diazepam Oral Solution. These serious side effects may also include delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing. Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these serious side effects. o You can develop an addiction even if you take Diazepam Oral Solution exactly as prescribed by your healthcare provider. o Take Diazepam Oral Solution exactly as your healthcare provider prescribed. o Do not share your Diazepam Oral Solution with other people. o Keep Diazepam Oral Solution in a safe place and away from children. Properly dispose of any unused medicine. • Physical dependence and withdrawal reactions. Diazepam Oral Solution can cause physical dependence and withdrawal reactions. o Do not suddenly stop taking Diazepam Oral Solution. Stopping Diazepam Oral Solution suddenly can cause serious and life-threatening side effects, including, unusual movements, responses, or expressions, seizures, sudden and severe mental or nervous system changes, depression, seeing or hearing things that others do not see or hear, an extreme increase in activity or talking, losing touch with reality, and suicidal thoughts or actions. Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these symptoms. o Some people who suddenly stop benzodiazepines have symptoms that can last for several weeks to more than 12 months, including, anxiety, trouble remembering, learning, or concentrating, depression, problems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling feeling in your hands, arms, legs or feet, and ringing in your ears. o Physical dependence is not the same as drug addiction. Your healthcare provider can tell you more about the differences between physical dependence and drug addiction. o Do not take more Diazepam Oral Solution than prescribed or take Diazepam Oral Solution for longer than prescribed. • Diazepam Oral Solution can make you sleepy or dizzy and can slow your thinking and motor skills. o Do not drive, operate heavy machinery, or do other dangerous activities during treatment with Diazepam Oral Solution. o Do not drink alcohol or take other drugs that may make you sleepy or dizzy during treatment with Diazepam Oral Solution without first talking to your healthcare provider. When taken with alcohol or drugs that cause sleepiness or dizziness, Diazepam Oral Solution may make your sleepiness or dizziness much worse. • Suicide actions and thoughts. Like other antiepileptic drugs, Diazepam Oral Solution may cause suicidal thoughts or actions in a very small number of people, about 1 in 500, including when it is used for other indications besides seizures. Tell your healthcare provider right away if you get any of these symptoms, especially if they are new, worse, or worry you: o thoughts about suicide or dying o new or worse depression o feeling agitated or restless o trouble sleeping (insomnia) o acting aggressive, being angry or violent o other unusual changes in behavior or mood o suicide attempts o new or worse anxiety or irritability o an extreme increase in activity and talking (mania) o new or worse panic attacks o acting on dangerous impulses How can I watch for early symptoms of suicidal thoughts and actions? o Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. o Keep all follow-up visits with your healthcare provider as scheduled. Tell your healthcare provider between visits as needed, especially if you are worried about symptoms. Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. See “ What are the possible side effects of Diazepam Oral Solution? ” for more information about side effects. What is Diazepam Oral Solution? Diazepam Oral Solution is a prescription medicine used: • to treat anxiety disorders • short-term to treat anxiety symptoms • To treat symptoms of suddenly stopping drinking alcohol (acute alcohol withdrawal) which can include shaking (tremor), agitation, seeing or hearing things that others do not see or hear (hallucinations), and sudden and severe mental or nervous system changes (delirium tremens) • along with other medicines to treat muscle spasms from: o injuries or strains o certain neurological conditions o a movement disorder called athetosis o stiff-person syndrome • along with other medicines to treat seizure disorders Diazepam Oral Solution is a federal controlled substance (C-IV) because it contains diazepam that can be abused or lead to dependence. Keep Diazepam Oral Solution in a safe place to prevent misuse and abuse. Selling or giving away Diazepam Oral Solution may harm others and is against the law. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs. It is not known if Diazepam Oral Solution is effective for use for longer than 4 months. Diazepam Oral Solution is not recommended alone as maintenance therapy for the treatment of seizure disorders. Diazepam Oral Solution is not recommended for use in children less than 6 months of age. Who should not take Diazepam Oral Solution? Do not take Diazepam Oral Solution if you: • are allergic to diazepam or any of the ingredients in Diazepam Oral Solution. See the end of this Medication Guide for a complete list of ingredients in Diazepam Oral Solution. • have an eye problem called acute narrow-angle glaucoma Before taking Diazepam Oral Solution, tell your healthcare provider about all of your medical conditions, including if you: • have a history of drug or alcohol abuse • have or had depression, mood problems, or suicidal thoughts or behavior • have lung or breathing problems • have liver or kidney problems • are pregnant or plan to become pregnant. o Taking Diazepam Oral Solution late in pregnancy can cause your baby to have symptoms of sedation (breathing problems, sluggishness, low muscle tone) and/or withdrawal symptoms (jitteriness, irritability, restlessness, shaking, excessive crying, feeding problems). o Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with Diazepam Oral Solution. o There are pregnancy registries for women who take Diazepam Oral Solution during pregnancy. The purpose of these registries is to collect information about the health of you and your baby. If you become pregnant during treatment with Diazepam Oral Solution, talk to your healthcare provider about registering with the appropriate registry: ▪ the National Pregnancy Registry for Psychiatric Medications by calling 1-866-961-2388 or visiting https://womensmentalhealth.org/researchpregnancyregistry/ . ▪ the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/ . • are breastfeeding or plan to breastfeed. Diazepam passes into your breast milk. o Talk to your healthcare provider about the best way to feed your baby during treatment with Diazepam Oral Solution. o If you breastfeed during treatment with Diazepam Oral Solution, monitor your baby for excessive sleepiness, poor feeding, and poor weight gain. Get medical help right away if your baby gets any of these symptoms. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking Diazepam Oral Solution with certain other medicines can cause side effects or affect how well Diazepam Oral Solution or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider. How should I take Diazepam Oral Solution? • Take Diazepam Oral Solution exactly as your healthcare provider tells you to take it. • Your healthcare provider will tell you how much Diazepam Oral Solution to take and when to take it. • Do not stop taking Diazepam Oral Solution without first talking to your healthcare provider. Your healthcare provider will tell you how to slowly stop Diazepam Oral Solution to avoid withdrawal symptoms. See “ What is the most important information I should know about Diazepam Oral Solution? ” • If you take too much Diazepam Oral Solution, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. What should I avoid while taking Diazepam Oral Solution? • See “ What are the possible side effects of Diazepam Oral Solution? ” • Avoid eating grapefruit or drinking grapefruit juice during treatment with Diazepam Oral Solution. What are the possible side effects of Diazepam Oral Solution? Diazepam Oral Solution may cause serious side effects, including: • See “ What is the most important information I should know about Diazepam Oral Solution? ” • Worsening of preexisting depression. Tell your healthcare provider if you get symptoms of worsening depression. • Abnormal thoughts and behavior (paradoxical reactions). Symptoms include aggressive behavior, agitation, anger, irritability, confusion, beliefs that are not true, hallucinations, anxiety, nightmares, and increased muscle stiffness or tightness. These reactions are more likely to happen in children and elderly people. Tell your healthcare provider if you get any of these symptoms. • Slowed and stopped breathing that may lead to death when benzodiazepines, including Diazepam Oral Solution, are taken alone or with certain other medicines. Slowed and stopped breathing has happened in people who have breathing problems and take benzodiazepines like Diazepam Oral Solution. Tell your healthcare provider right away if you get any breathing problems. • Increase in eye pressure in people with open-angle glaucoma. See “ Who should not take Diazepam Oral Solution? ” The most common side effects of Diazepam Oral Solution include: • drowsiness • tiredness • muscle weakness • loss of control of body movements (ataxia) These are not all the possible side effects of Diazepam Oral Solution. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Hikma Pharmaceuticals USA Inc. at 1-800-962-8364. How should I store Diazepam Oral Solution? • Store Diazepam Oral Solution at room temperature between 68°F to 77°F (20°C to 25°C). • Keep Diazepam Oral Solution in a tightly closed container and out of light. Keep Diazepam Oral Solution and all medicines out of the reach of children. General information about the safe and effective use of Diazepam Oral Solution. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Diazepam Oral Solution for a condition for which it was not prescribed. Do not give Diazepam Oral Solution to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Diazepam Oral Solution that is written for health professionals. What are the ingredients in Diazepam Oral Solution? Active ingredient: Each 5 mL of Diazepam Oral Solution contains 5 mg diazepam, USP. Inactive ingredients: The flavored 5 mg/5 mL oral solution contains bitterness modifier, citric acid, D&C Yellow No. 10, FD&C Red No. 40, polyethylene glycol, propylene glycol, sodium citrate, sorbitol, water and wintergreen coriander spice blend. Distributed by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 C50001281/02 This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: October 2026"],"spl_medguide_table":["<table styleCode=\"Noautorules\" width=\"100%\"> <col width=\"100%\"/> <tbody> <tr> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">MEDICATION GUIDE</content> </paragraph> <paragraph> <content styleCode=\"bold\">Diazepam Oral Solution, C-IV, 5 mg per 5 mL</content> </paragraph> <paragraph> <content styleCode=\"bold\">(dye az&#x2B9; e pam)</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">What is the most important information I should know about Diazepam Oral Solution?</content> </paragraph> <paragraph> <content styleCode=\"bold\">Diazepam Oral Solution may cause serious side effects, including:</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption> <content styleCode=\"bold\">Diazepam Oral Solution is a benzodiazepine medicine. Taking benzodiazepines with opioid medicines, alcohol, or other central nervous system (CNS) depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death.</content> Get emergency help right away if any of the following happens:<list listType=\"unordered\"> <item> <caption>o</caption>shallow or slowed breathing,</item> <item> <caption>o</caption>breathing stops (which may lead to the heart stopping),</item> <item> <caption>o</caption>excessive sleepiness (sedation).</item> </list> </item> <item> <caption>&#x2022;</caption> <content styleCode=\"bold\">Risk of abuse, misuse, and addiction.</content> There is a risk of abuse, misuse, and addiction with benzodiazepines, including Diazepam Oral Solution, which can lead to overdose and serious side effects including coma and death.<list listType=\"unordered\"> <item> <caption>o</caption> <content styleCode=\"bold\">Serious side effects including coma and death have happened in people who have abused or misused benzodiazepines, including Diazepam Oral Solution.</content> These serious side effects may also include delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing. <content styleCode=\"bold\">Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these serious side effects.</content> </item> <item> <caption>o</caption> <content styleCode=\"bold\">You can develop an addiction even if you take Diazepam Oral Solution exactly as prescribed by your healthcare provider.</content> </item> <item> <caption>o</caption> <content styleCode=\"bold\">Take Diazepam Oral Solution exactly as your healthcare provider prescribed.</content> </item> <item> <caption>o</caption> <content styleCode=\"bold\">Do not</content> share your Diazepam Oral Solution with other people.</item> <item> <caption>o</caption>Keep Diazepam Oral Solution in a safe place and away from children. Properly dispose of any unused medicine.</item> </list> </item> <item> <caption>&#x2022;</caption> <content styleCode=\"bold\">Physical dependence and withdrawal reactions.</content> Diazepam Oral Solution can cause physical dependence and withdrawal reactions.<list listType=\"unordered\"> <item> <caption>o</caption> <content styleCode=\"bold\">Do not suddenly stop taking Diazepam Oral Solution. </content>Stopping Diazepam Oral Solution suddenly can cause serious and life-threatening side effects, including, unusual movements, responses, or expressions, seizures, sudden and severe mental or nervous system changes, depression, seeing or hearing things that others do not see or hear, an extreme increase in activity or talking, losing touch with reality, and suicidal thoughts or actions. <content styleCode=\"bold\">Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these symptoms.</content> </item> <item> <caption>o</caption> <content styleCode=\"bold\">Some people who suddenly stop benzodiazepines have symptoms that can last for several weeks to more than 12 months,</content> including, anxiety, trouble remembering, learning, or concentrating, depression, problems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling feeling in your hands, arms, legs or feet, and ringing in your ears.</item> <item> <caption>o</caption>Physical dependence is not the same as drug addiction. Your healthcare provider can tell you more about the differences between physical dependence and drug addiction.</item> <item> <caption>o</caption> <content styleCode=\"bold\">Do not</content> take more Diazepam Oral Solution than prescribed or take Diazepam Oral Solution for longer than prescribed.</item> </list> </item> <item> <caption>&#x2022;</caption> <content styleCode=\"bold\">Diazepam Oral Solution can make you sleepy or dizzy and can slow your thinking and motor skills.</content> <list listType=\"unordered\"> <item> <caption>o</caption> <content styleCode=\"bold\">Do not</content> drive, operate heavy machinery, or do other dangerous activities during treatment with Diazepam Oral Solution.</item> <item> <caption>o</caption> <content styleCode=\"bold\">Do not</content> drink alcohol or take other drugs that may make you sleepy or dizzy during treatment with Diazepam Oral Solution without first talking to your healthcare provider. When taken with alcohol or drugs that cause sleepiness or dizziness, Diazepam Oral Solution may make your sleepiness or dizziness much worse.</item> </list> </item> <item> <caption>&#x2022;</caption> <content styleCode=\"bold\">Suicide actions and thoughts. Like other antiepileptic drugs, Diazepam Oral Solution may cause suicidal thoughts or actions in a very small number of people, about 1 in 500,</content> including when it is used for other indications besides seizures.</item> <item> <caption> </caption> <content styleCode=\"bold\">Tell your healthcare provider right away if you get any of these symptoms, especially if they are new, worse, or worry you:</content> <list listType=\"ordered\"> <item> <caption>o</caption>thoughts about suicide or dying</item> <item> <caption>o</caption>new or worse depression</item> <item> <caption>o</caption>feeling agitated or restless</item> <item> <caption>o</caption>trouble sleeping (insomnia)</item> <item> <caption>o</caption>acting aggressive, being angry or violent</item> <item> <caption>o</caption>other unusual changes in behavior or mood</item> <item> <caption>o</caption>suicide attempts</item> <item> <caption>o</caption>new or worse anxiety or irritability</item> <item> <caption>o</caption>an extreme increase in activity and talking (mania)</item> <item> <caption>o</caption>new or worse panic attacks</item> <item> <caption>o</caption>acting on dangerous impulses</item> </list> </item> <item> <caption> </caption> <content styleCode=\"bold\">How can I watch for early symptoms of suicidal thoughts and actions?</content> <list listType=\"ordered\"> <item> <caption>o</caption>Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.</item> <item> <caption>o</caption>Keep all follow-up visits with your healthcare provider as scheduled.</item> </list> </item> <item> <caption> </caption>Tell your healthcare provider between visits as needed, especially if you are worried about symptoms. Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.</item> </list> <paragraph>See &#x201C;<content styleCode=\"bold\">What are the possible side effects of Diazepam Oral Solution?</content>&#x201D; for more information about side effects.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">What is Diazepam Oral Solution?</content> </paragraph> <paragraph>Diazepam Oral Solution is a prescription medicine used:</paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>to treat anxiety disorders</item> <item> <caption>&#x2022;</caption>short-term to treat anxiety symptoms</item> <item> <caption>&#x2022;</caption>To treat symptoms of suddenly stopping drinking alcohol (acute alcohol withdrawal) which can include shaking (tremor), agitation, seeing or hearing things that others do not see or hear (hallucinations), and sudden and severe mental or nervous system changes (delirium tremens)</item> <item> <caption>&#x2022;</caption>along with other medicines to treat muscle spasms from:<list listType=\"unordered\"> <item> <caption>o</caption>injuries or strains</item> <item> <caption>o</caption>certain neurological conditions</item> <item> <caption>o</caption>a movement disorder called athetosis</item> <item> <caption>o</caption>stiff-person syndrome</item> </list> </item> <item> <caption>&#x2022;</caption>along with other medicines to treat seizure disorders</item> </list> <paragraph> <content styleCode=\"bold\">Diazepam Oral Solution is a federal controlled substance (C-IV) because it contains diazepam that can be abused or lead to dependence.</content> Keep Diazepam Oral Solution in a safe place to prevent misuse and abuse. Selling or giving away Diazepam Oral Solution may harm others and is against the law. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs.</paragraph> <paragraph>It is not known if Diazepam Oral Solution is effective for use for longer than 4 months.</paragraph> <paragraph>Diazepam Oral Solution is not recommended alone as maintenance therapy for the treatment of seizure disorders.</paragraph> <paragraph>Diazepam Oral Solution is not recommended for use in children less than 6 months of age.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Who should not take Diazepam Oral Solution?</content> </paragraph> <paragraph> <content styleCode=\"bold\">Do not take Diazepam Oral Solution if you:</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>are allergic to diazepam or any of the ingredients in Diazepam Oral Solution. See the end of this Medication Guide for a complete list of ingredients in Diazepam Oral Solution.</item> <item> <caption>&#x2022;</caption>have an eye problem called acute narrow-angle glaucoma</item> </list> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Before taking Diazepam Oral Solution, tell your healthcare provider about all of your medical conditions, including if you:</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>have a history of drug or alcohol abuse</item> <item> <caption>&#x2022;</caption>have or had depression, mood problems, or suicidal thoughts or behavior</item> <item> <caption>&#x2022;</caption>have lung or breathing problems</item> <item> <caption>&#x2022;</caption>have liver or kidney problems</item> <item> <caption>&#x2022;</caption>are pregnant or plan to become pregnant.<list listType=\"unordered\"> <item> <caption>o</caption>Taking Diazepam Oral Solution late in pregnancy can cause your baby to have symptoms of sedation (breathing problems, sluggishness, low muscle tone) and/or withdrawal symptoms (jitteriness, irritability, restlessness, shaking, excessive crying, feeding problems).</item> <item> <caption>o</caption>Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with Diazepam Oral Solution.</item> <item> <caption>o</caption>There are pregnancy registries for women who take Diazepam Oral Solution during pregnancy. The purpose of these registries is to collect information about the health of you and your baby. If you become pregnant during treatment with Diazepam Oral Solution, talk to your healthcare provider about registering with the appropriate registry:<list listType=\"unordered\"> <item> <caption>&#x25AA;</caption>the National Pregnancy Registry for Psychiatric Medications by calling 1-866-961-2388 or visiting <linkHtml href=\"https://womensmentalhealth.org/researchpregnancyregistry/\">https://womensmentalhealth.org/researchpregnancyregistry/</linkHtml>.</item> <item> <caption>&#x25AA;</caption>the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334 or visiting <linkHtml href=\"http://www.aedpregnancyregistry.org/\">http://www.aedpregnancyregistry.org/</linkHtml>.</item> </list> </item> </list> </item> <item> <caption>&#x2022;</caption>are breastfeeding or plan to breastfeed. Diazepam passes into your breast milk.<list listType=\"unordered\"> <item> <caption>o</caption>Talk to your healthcare provider about the best way to feed your baby during treatment with Diazepam Oral Solution.</item> <item> <caption>o</caption>If you breastfeed during treatment with Diazepam Oral Solution, monitor your baby for excessive sleepiness, poor feeding, and poor weight gain. Get medical help right away if your baby gets any of these symptoms.</item> </list> </item> </list> <paragraph> <content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking Diazepam Oral Solution with certain other medicines can cause side effects or affect how well Diazepam Oral Solution or the other medicines work. <content styleCode=\"bold\">Do not</content> start or stop other medicines without talking to your healthcare provider.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">How should I take Diazepam Oral Solution?</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>Take Diazepam Oral Solution exactly as your healthcare provider tells you to take it.</item> <item> <caption>&#x2022;</caption>Your healthcare provider will tell you how much Diazepam Oral Solution to take and when to take it.</item> <item> <caption>&#x2022;</caption> <content styleCode=\"bold\">Do not</content> stop taking Diazepam Oral Solution without first talking to your healthcare provider. Your healthcare provider will tell you how to slowly stop Diazepam Oral Solution to avoid withdrawal symptoms. See &#x201C;<content styleCode=\"bold\">What is the most important information I should know about Diazepam Oral Solution?</content>&#x201D;</item> <item> <caption>&#x2022;</caption>If you take too much Diazepam Oral Solution, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.</item> </list> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">What should I avoid while taking Diazepam Oral Solution?</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>See &#x201C;<content styleCode=\"bold\">What are the possible side effects of Diazepam Oral Solution?</content>&#x201D;</item> <item> <caption>&#x2022;</caption>Avoid eating grapefruit or drinking grapefruit juice during treatment with Diazepam Oral Solution.</item> </list> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">What are the possible side effects of Diazepam Oral Solution?</content> </paragraph> <paragraph> <content styleCode=\"bold\">Diazepam Oral Solution may cause serious side effects, including:</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>See &#x201C;<content styleCode=\"bold\">What is the most important information I should know about Diazepam Oral Solution?</content>&#x201D;</item> <item> <caption>&#x2022;</caption> <content styleCode=\"bold\">Worsening of preexisting depression.</content> Tell your healthcare provider if you get symptoms of worsening depression.</item> <item> <caption>&#x2022;</caption> <content styleCode=\"bold\">Abnormal thoughts and behavior (paradoxical reactions).</content> Symptoms include aggressive behavior, agitation, anger, irritability, confusion, beliefs that are not true, hallucinations, anxiety, nightmares, and increased muscle stiffness or tightness. These reactions are more likely to happen in children and elderly people. Tell your healthcare provider if you get any of these symptoms.</item> <item> <caption>&#x2022;</caption> <content styleCode=\"bold\">Slowed and stopped breathing</content> that may lead to death when benzodiazepines, including Diazepam Oral Solution, are taken alone or with certain other medicines. Slowed and stopped breathing has happened in people who have breathing problems and take benzodiazepines like Diazepam Oral Solution. Tell your healthcare provider right away if you get any breathing problems.</item> <item> <caption>&#x2022;</caption> <content styleCode=\"bold\">Increase in eye pressure in people with open-angle glaucoma.</content> See &#x201C;<content styleCode=\"bold\">Who should not take Diazepam Oral Solution?</content>&#x201D;</item> </list> <paragraph> <content styleCode=\"bold\">The most common side effects of Diazepam Oral Solution include:</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>drowsiness</item> <item> <caption>&#x2022;</caption>tiredness</item> <item> <caption>&#x2022;</caption>muscle weakness</item> <item> <caption>&#x2022;</caption>loss of control of body movements (ataxia)</item> </list> <paragraph>These are not all the possible side effects of Diazepam Oral Solution.</paragraph> <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph> <paragraph>You may also report side effects to Hikma Pharmaceuticals USA Inc. at 1-800-962-8364.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">How should I store Diazepam Oral Solution?</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>Store Diazepam Oral Solution at room temperature between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C).</item> <item> <caption>&#x2022;</caption>Keep Diazepam Oral Solution in a tightly closed container and out of light.</item> </list> <paragraph> <content styleCode=\"bold\">Keep Diazepam Oral Solution and all medicines out of the reach of children.</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">General information about the safe and effective use of Diazepam Oral Solution.</content> </paragraph> <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Diazepam Oral Solution for a condition for which it was not prescribed. Do not give Diazepam Oral Solution to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Diazepam Oral Solution that is written for health professionals.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">What are the ingredients in Diazepam Oral Solution?</content> </paragraph> <paragraph> <content styleCode=\"bold\">Active ingredient:</content> </paragraph> <paragraph>Each 5 mL of Diazepam Oral Solution contains 5 mg diazepam, USP.</paragraph> <paragraph> <content styleCode=\"bold\">Inactive ingredients:</content> </paragraph> <paragraph>The flavored 5 mg/5 mL oral solution contains bitterness modifier, citric acid, D&amp;C Yellow No. 10, FD&amp;C Red No. 40, polyethylene glycol, propylene glycol, sodium citrate, sorbitol, water and wintergreen coriander spice blend.</paragraph> <paragraph>Distributed by:</paragraph> <paragraph> <content styleCode=\"bold\">Hikma Pharmaceuticals USA Inc.</content> </paragraph> <paragraph>Berkeley Heights, NJ 07922</paragraph> <paragraph> <content styleCode=\"bold\">C50001281/02</content> </paragraph> </td> </tr> </tbody> </table>"],"spl_product_data_elements":["Diazepam Diazepam DIAZEPAM DIAZEPAM ANHYDROUS CITRIC ACID D&C YELLOW NO. 10 FD&C RED NO. 40 POLYETHYLENE GLYCOL 1000 PROPYLENE GLYCOL SODIUM CITRATE, UNSPECIFIED FORM SORBITOL WATER"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS • Pregnancy: Based on animal data, may cause fetal harm ( 8.1 ) • Pediatric Use: Not recommended in pediatric patients less than 6 months of age ( 8.4 ) • Hepatic Impairment: Patients with hepatic impairment are more sensitive to adverse reactions of diazepam ( 8.6 ) 8.1 Pregnancy Pregnancy Exposure Registries There are pregnancy exposure registries that monitor pregnancy outcomes in women exposed to psychiatric medications and antiepileptic drugs (AEDs), including diazepam, during pregnancy. Healthcare providers are encouraged to advise patients to register by contacting the appropriate registry below: • The National Pregnancy Registry for Psychiatric Medications by calling 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/othermedications/. • The North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334 or online at http://www.aedpregnancyregistry.org/. Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see Warnings and Precautions ( 5.10 ) and Clinical Considerations] . Available data from published observational studies of pregnant women exposed to benzodiazepines do not support a clear association with benzodiazepines and major birth defects (see Data) . There are risks to the mother and fetus associated with untreated epilepsy during pregnancy (see Clinical Considerations) . In animal studies, administration of diazepam during the organogenesis period of pregnancy resulted in increased incidences of fetal malformations at doses greater than those used clinically. Data for diazepam and other benzodiazepines suggest the possibility of increased neuronal cell death and long-term effects on neurobehavioral and immunological function based on findings in animals following prenatal or early postnatal exposure at clinically relevant doses (see Data) . The background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryofetal Risk Epilepsy, with or without exposure to antiepileptic drugs, has been associated with several adverse outcomes during pregnancy, including preeclampsia, preterm labor, antepartum and postpartum hemorrhage, placental abruption, poor fetal growth, prematurity, fetal death, and maternal mortality. The risk of maternal or fetal injury may be greatest for patients with untreated or poorly controlled convulsive seizures. Females with epilepsy should not discontinue diazepam abruptly due to the risk of status epilepticus or severe seizures, which may be life-threatening [see Warnings and Precautions ( 5.3 )] . Fetal/Neonatal Adverse Reactions Benzodiazepines cross the placenta and may produce respiratory depression, hypotonia, and sedation in neonates. Monitor neonates exposed to diazepam during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor neonates exposed to diazepam during pregnancy for signs of withdrawal. Manage these neonates accordingly [see Warnings and Precautions ( 5.10 )] . Data Human Data Published data from observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects. Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, recent case-control and cohort studies of benzodiazepine use during pregnancy were adjusted for confounding exposures to alcohol, tobacco and other medications; these studies did not support an association with benzodiazepines and major birth defects. Animal Data Diazepam has been shown to cause malformations when administered orally to pregnant mice and hamsters during the period of organogenesis at doses of 100 mg/kg/day or greater, approximately 12 and 20 times the maximum recommended human dose (MRHD) based on mg/m 2 body surface area, respectively. Cleft palate and encephalopathy were the most common and consistently reported malformations produced at maternally toxic doses of diazepam. Rodent studies have indicated that prenatal exposure to diazepam doses similar to those used clinically can produce long-term changes in cellular immune responses, brain neurochemistry, and behavior. In published animal studies, administration of benzodiazepines or other drugs that enhance GABAergic inhibition to neonatal rats has been reported to result in widespread apoptotic neurodegeneration in the developing brain at clinically relevant plasma concentrations. The window of vulnerability to these changes in rats (postnatal days 0 to 14) includes a period of brain development that takes place during the third trimester of pregnancy in humans. 8.2 Lactation Risk Summary Diazepam and its active metabolite, N-methyldiazepam, are present in breastmilk. There are reports of sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk (see Clinical Considerations) . There are no data on the effects of diazepam and/or its active metabolite on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for diazepam and any potential adverse effects on the breastfed infant from diazepam or from the underlying maternal condition. Clinical Considerations Infants exposed to diazepam through breastmilk should be monitored for sedation, poor feeding, and poor weight gain. 8.4 Pediatric Use Diazepam oral solution is indicated for use in pediatric patients for the: • Treatment of anxiety disorders • Short-term treatment of anxiety symptoms • Treatment of tremor, acute agitation, hallucinosis, and impending delirium tremens or delirium tremens in acute alcohol withdrawal • Adjunctive treatment of skeletal muscle spasm due to: o reflex spasm to local pathology o spasticity caused by upper motor neuron disorders o athetosis o stiff-person syndrome • Adjunctive treatment of seizure disorders Paradoxical reactions are more likely to occur in pediatric patients than in adult patients [see Warnings and Precautions ( 5.7 )] . Diazepam is not recommended for use in pediatric patients less than 6 months of age. Prolonged central nervous system depression has been observed in neonates treated with diazepam. 8.5 Geriatric Use Extensive accumulation of diazepam and its major metabolite, des-methyldiazepam, has been noted following chronic administration of diazepam in healthy geriatric male subjects [see Clinical Pharmacology ( 12.3 )] . Metabolites of diazepam are substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function than in patients with normal renal function. Because geriatric patients are more likely to have decreased renal function, care should be taken in dosage selection. A lower starting dosage is recommended, and the dosage should be increased gradually as needed and tolerated, to reduce the risk of adverse reactions [see Dosage and Administration ( 2.2 )] . Paradoxical reactions are more likely to occur in geriatric patients compared to younger adult patients [see Warning and Precautions ( 5.7 )] . 8.6 Hepatic Impairment Patients with hepatic impairment are more sensitive to adverse reactions associated with diazepam, including increased susceptibility to sedation and delirium [Clinical Pharmacology ( 12.3 )] . The recommended dosage of diazepam in patients with mild or moderate hepatic impairment is half the recommended dosage as those with normal hepatic function [see Dosage and Administration ( 2.2 )] . Diazepam is not recommended in patients with severe hepatic impairment. 8.7 Impaired Respiratory Function In patients with impaired respiratory function, respiratory depression and apnea have been reported with use of benzodiazepines. Use diazepam with caution in patients with impaired respiratory function related to a concurrent disease process. If signs and symptoms of respiratory depression or apnea occur, consider discontinuing diazepam [Warnings and Precautions ( 5.8 )] . 8.8 Debilitated Patients Debilitated patients are at an increased risk of adverse reactions to diazepam. A lower starting dosage is recommended, and the dosage should be increased gradually as needed and tolerated, to reduce the risks of adverse reactions [see Dosage and Administration ( 2.2 )] ."],"version":"9","warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Central Nervous System (CNS) Depression: Caution patients against engaging in hazardous occupations or activities requiring complete mental alertness (e.g., operating machinery or driving a motor vehicle). Avoid alcohol and use other medications that produce CNS depression with caution ( 5.4 , 7.2 ) • Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behavior ( 5.5 ) • Worsening of Preexisting Depression: Monitor for worsening of preexisting depression ( 5.6 ) • Paradoxical Reactions: Gradually discontinue diazepam if paradoxical reactions occur ( 5.7 ) • Respiratory Depression and Apnea: Use with caution in patients with impaired respiratory function related to concurrent disease process. Consider discontinuing diazepam if signs and symptoms of respiratory depression or apnea occur in any patient ( 5.8 ) • Glaucoma: Can increase intraocular pressure in patients with glaucoma. May be used in patients with open-angle glaucoma only if receiving appropriate therapy ( 4 , 5.9 ) • Neonatal Sedation and Withdrawal Syndrome: Diazepam use during pregnancy can result in neonatal sedation and/or neonatal withdrawal syndrome. ( 5.10 , 8.1 ) 5.1 Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including diazepam, and opioids may result in profound sedation, respiratory depression, coma, and death [see Drug Interactions ( 7.1 )] . Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe diazepam concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of diazepam than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking diazepam, prescribe a lower initial dose of the opioid and titrate based upon clinical response. Advise both patients and caregivers about the risks of respiratory depression and sedation when diazepam is used with opioids. 5.2 Abuse, Misuse, and Addiction The use of benzodiazepines, including diazepam, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death [see Drug Abuse and Dependence ( 9.2 )] . Before prescribing diazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of diazepam, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of diazepam along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate. 5.3 Dependence and Withdrawal Reactions To reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam or reduce the dosage (a patient-specific plan should be used to taper the dose) [see Dosage and Administration ( 2.3 )] . Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use. Acute Withdrawal Reactions The continued use of benzodiazepines, including diazepam, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of diazepam after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) [see Drug Abuse and Dependence ( 9.3 )] . Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months [see Drug Abuse and Dependence ( 9.3 )] . 5.4 Central Nervous System Depression Benzodiazepines, including diazepam, may produce central nervous system (CNS) depression. Caution patients receiving diazepam against engaging in hazardous occupations or activities requiring complete mental alertness (e.g., operating machinery or driving a motor vehicle). Alcohol should be avoided and medications that produce CNS depression should be used with caution during treatment with diazepam [see Drug Interactions ( 7.2 )] . 5.5 Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including diazepam, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Table 2 shows absolute and relative risk by indication for all evaluated AEDs. Table 2: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis Indication Placebo Patients with Events Per 1,000 Patients Drug Patients with Events Per 1,000 Patients Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients Risk Differences: Additional Drug Patients with Events Per 1,000 Patients Epilepsy 1.0 3.4 3.5 2.4 Psychiatric 5.7 8.5 1.5 2.9 Other 1.0 1.8 1.9 0.9 Total 2.4 4.3 1.8 1.9 The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone considering prescribing diazepam or any other AED must balance the risk of suicidal thoughts or behaviors with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. 5.6 Worsening of Preexisting Depression Benzodiazepines, including diazepam, may worsen preexisting depression [see Warnings and Precautions ( 5.5 )] . Monitor patients for worsening of preexisting depression. Appropriate precautions (e.g., limiting the total prescription size) should be considered. 5.7 Paradoxical Reactions Paradoxical reactions, such as aggression, agitation, anger, irritability, psychoses, hallucinations, anxiety, nightmares, and increased muscle spasticity have been reported during benzodiazepine use [see Adverse Reactions ( 6 )] . These reactions are more likely to occur in pediatric and geriatric patients. Gradually discontinue diazepam if paradoxical reactions occur [see Dosage and Administration ( 2.3 )] . 5.8 Respiratory Depression and Apnea Use of benzodiazepines, including diazepam, either alone or in combination with other CNS depressants, may lead to potentially fatal respiratory depression [see Warnings and Precautions ( 5.4 )] . In patients with impaired respiratory function treated with benzodiazepines, respiratory depression and apnea have been reported. Use diazepam with caution in patients with impaired respiratory function related to a concurrent disease process [see Use in Specific Populations ( 8.7 )] . If signs and symptoms of respiratory depression or apnea occur in any patient, consider discontinuing diazepam. 5.9 Glaucoma Benzodiazepines, including diazepam, can increase intraocular pressure in patients with glaucoma. Diazepam may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. Diazepam is contraindicated in patients with acute narrow-angle glaucoma. 5.10 Neonatal Sedation and Withdrawal Syndrome Maternal use of diazepam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate. Monitor neonates exposed to diazepam during pregnancy or labor for signs of sedation and monitor neonates exposed to diazepam during pregnancy for signs of withdrawal; manage these neonates accordingly [see Use in Specific Populations ( 8.1 )] ."],"warnings_and_cautions_table":["<table styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 2: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis</caption> <col width=\"20%\"/> <col width=\"20%\"/> <col width=\"20%\"/> <col width=\"20%\"/> <col width=\"20%\"/> <tbody> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Indication</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Placebo Patients with Events Per 1,000 Patients</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Drug Patients with Events Per 1,000 Patients</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Risk Differences: Additional Drug Patients with Events Per 1,000 Patients</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Epilepsy</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.0</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.4</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.5</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.4</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Psychiatric</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>5.7</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>8.5</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.5</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.9</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Other</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.0</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.8</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.9</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.9</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Total</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>2.4</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>4.3</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>1.8</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>1.9</paragraph> </td> </tr> </tbody> </table>"]}